ERT market for rare lysosomal storage disorders to reach $7.24B by 2030

The enzyme replacement therapy market for rare lysosomal storage disorders rose to $4.69 billion in 2026 and is projected to hit $7.24 billion by 2030. Growth is being driven by better diagnosis, personalized medicine, and higher investment in rare-disease treatment, with North America leading and Asia-Pacific expected to grow fastest.

Why it matters: - Enzyme replacement therapy is a core treatment path for rare lysosomal storage disorders, which require long-term specialty care. - The market’s growth signals more diagnosis, more treatment access, and more spending on rare-disease biologics. - The market is moving from $4.19 billion in 2025 to $4.69 billion in 2026, then to $7.24 billion by 2030. - The 2025-to-2026 increase reflects an 11.9% compound annual growth rate. - The 2026-to-2030 forecast reflects an 11.5% compound annual growth rate.

What happened: - The Business Research Company published a 2026 global market report on enzyme replacement therapy for rare lysosomal storage disorders. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to post the fastest growth over the forecast period. - The market analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample report is available. - A full report is also available.

The details: - Enzyme replacement therapy uses synthetic or recombinant enzymes that patients with lysosomal storage disorders lack or do not produce in enough quantity. - The treatment helps restore cellular function and reduce the buildup of toxic substances. - Improved diagnosis rates are expanding the patient pool for treatment. - Broader access to recombinant biologic therapies is supporting adoption. - Awareness campaigns for rare diseases are increasing demand. - Pediatric genetic screening programs are identifying more patients earlier. - Higher healthcare spending on specialty biologics is adding momentum. - The report points to gene editing and enzyme engineering as major drivers of future growth. - Wider use of personalized treatment strategies is expected to support adoption. - Orphan drug development investment is rising. - Global treatment infrastructure is expanding. - Home-based infusion and patient-centered care models are becoming more important. - Next-generation gene-edited enzyme therapies are expected to improve cellular uptake and efficiency. - Pegylated enzyme formulations are expected to reduce infusion frequency and improve adherence. - Nanoparticle-based delivery systems are emerging for targeted tissue therapy. - Precision dosing strategies are gaining traction. - Recombinant enzyme production using mammalian and plant platforms is expected to improve yield and stability.

Between the lines: - The market is being pulled by both medical need and policy support. - Government incentives such as orphan drug policies, tax benefits and regulatory support are helping make rare-disease programs more commercially viable. - The financing environment also appears strong. Global Genes reported that companies developing rare disease drugs raised $7.1 billion in public equity and debt financing in the first quarter of 2024, up 307% from the same period in 2023. - Personalized medicine is becoming a bigger competitive factor as genetic testing makes it easier to match patients with the right therapy. - The Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - That shift suggests future competition will center on better targeting, easier administration and stronger adherence, not just broader availability.

What's next: - The market is expected to keep expanding through 2030 as more patients are diagnosed and treated. - Gene-edited enzymes, delivery improvements and precision dosing are likely to shape product development. - Treatment access may improve as more countries expand orphan-drug frameworks and specialty care infrastructure. - Home infusion models could become more important as providers look for ways to reduce treatment burden.

The bottom line: - Rare-disease enzyme replacement therapy is moving from a niche specialty segment to a faster-growing global biologics market, with innovation and diagnosis rates driving the next leg of growth.